Transparency Market Research

Anatomic Pathology Testing Market: Asia Pacific Is a Lucrative Market Owing to the Rising Investment by Governments

 

Albany, NY -- (SBWIRE) -- 07/30/2018 -- Anatomic pathology, or anatomical pathology, entails biochemical, microscopic, and molecular examination of tissues and organs to uncover abnormalities in them. This helps to diagnose diseases and manage treatment. Although most commonly used to detect and manage different kinds of cancer and tumors, it is also useful in evaluating other health conditions such as kidney and liver diseases, infections, and autoimmune diseases.

The two different types of anatomic pathology testing products are instruments and consumables. Instruments include slides, microscope, centrifuges, and cassette printers, while consumables include reagents, kits, and antibodies. The two different services in the Anatomic Pathology Testing Market are cytopathology and histopathology. Anatomic pathology testing finds application in hospitals, clinical diagnostic laboratories, and physician office laboratories.

From a geographical standpoint, North America is a key region in the anatomic pathology testing market because of the growing prevalence of cancer and other chronic diseases. Europe is another key region and is propelled by the large pool of elderly population that is highly susceptible to chronic diseases and surging popularity of personalized medicine and digital laboratory.

Asia Pacific is a lucrative market owing to the rising investment by governments and academic institutions in diagnostic research and increasing awareness about anatomic pathology tests. In addition, globalization, improving economies, and changing lifestyle is also stoking growth in the market in the region.

Some of the prominent participants in the global anatomic pathology testing market are Neogenomics Laboratories, Inc., Abbott Diagnostic International Ltd., Danaher, Agilent Technologies, Bio SB, Roche Diagnostics, and Quest Diagnostics Incorporated.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26852



Anatomic pathology is a branch of science or branch of medicine that primarily involves microscopic, biochemical, and molecular examination of organs and tissues to find out the effectiveness of diseases. The key objective of anatomic pathology is to identify abnormalities in order to manage diagnosis and treatment. Anatomic pathology helps to detect various types of tumor and cancer. It is also sometimes useful to evaluate the liver and kidney diseases effectively. Gross examination, histopathology, immunohistochemistry, cytopathology, and flow immunophenotyping are some of the procedures carried out during anatomic pathology test. Anatomic pathology testing is a superspeciality test. To perform this type of test, a person should have a qualified certification from a recognized body such as the American Board of Pathology or the American Osteopathic Board of Pathology. Anatomic pathologist is also involved in post mortem examination. Like clinical pathology reports, anatomic pathology reports also contain essential elements such as name, number, sample type, and source. Many anatomic pathology departments operate according to the specific need of a patient.

Major players in the anatomic pathology testing market are Abbott Diagnostic International Ltd., Agilent Technologies, Danaher, Roche Diagnostics, Bio SB, Neogenomics Laboratories, Inc., and Quest Diagnostics Incorporated.

Enquiry for discount on this report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26852